Get the Stockscreener App
2.09
8.29%
0.16
After Hours:
2.04
-0.05
-2.39%
Alx Oncology Holdings Inc stock is traded at $2.09, with a volume of 690.14K.
It is up +8.29% in the last 24 hours and up +6.63% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.93
Open:
$1.91
24h Volume:
690.14K
Relative Volume:
0.72
Market Cap:
$281.23M
Revenue:
-
Net Income/Loss:
$-101.70M
P/E Ratio:
-1.1023
EPS:
-1.8961
Net Cash Flow:
$-84.35M
1W Performance:
+32.28%
1M Performance:
+6.63%
6M Performance:
+77.12%
1Y Performance:
+314.93%
1-Day Range:
$1.91
$2.09
1-Week Range:
$1.59
$2.09
52-Week Range:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.09 | 259.70M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Mar-06-26 | Resumed | UBS | Buy |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALXO Stock Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock - Yahoo Finance
ALXO Stock Price, Quote & Chart | ALX ONCOLOGY HOLDINGS INC (NASDAQ:ALXO) - ChartMill
ALX Oncology Holdings Inc Announces CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept and Zanidatamab Combination in Advanced Breast Cancer - marketscreener.com
BioAffinity stock surges 113.8% in 3 months: What's driving the rally? - MSN
ALX Oncology (ALXO) amendment shows Millennium affiliates report 1.99M shares - Stock Titan
ALXO (ALX Oncology Holdings Inc.) reports narrow Q4 2025 EPS miss sending shares 0.6% lower on mild investor disappointment.Sector Perform - UBND thành phố Hải Phòng
Buy or Sell? | ALX Oncology Holdings Inc. posts 0.1% EPS miss, no revenue dataRevision Downgrade - Xã Thanh Hà
ALX Oncology (ALXO) Stock Analysis: Buy or Sell? | ALX Oncology Holdings Inc. posts 0.1% EPS miss, no revenue dataMoat - Cổng thông tin điện tử Tỉnh Sơn La
ALXO Financials: Income Statement, Balance Sheet & Cash Flow | Alx Oncology Holdings Inc - Stock Titan
ALX Oncology | ARS: Annual Report to Security Holders - Moomoo
[ARS] ALX ONCOLOGY HOLDINGS INC SEC Filing - Stock Titan
[DEF 14A] ALX ONCOLOGY HOLDINGS INC Definitive Proxy Statement - Stock Titan
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - Sahm
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
ALXO PE Ratio & Valuation, Is ALXO Overvalued - Intellectia AI
Alx Oncology reports inducement grant as permitted by the Nasdaq Listing Rules - marketscreener.com
ALX Oncology (NASDAQ: ALXO) awards 800,000 options to chief officer - Stock Titan
ALX Oncology (ALXO) awards CMO 100,000 stock options at $1.68 - Stock Titan
Jeff Knight named reporting insider at ALX Oncology (NASDAQ: ALXO) with no trades - Stock Titan
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally? - The Globe and Mail
ALX Oncology Holdings Inc. Appoints Jeff Knight As Chief Development And Operating Officer, Effective April 13, 2026 - marketscreener.com
Stock Market Recap: Is ALX Oncology Holdings Inc a stock for growth or value investorsTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
ALX Oncology names Jeff Knight as chief development officer By Investing.com - Investing.com Australia
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer to Advance Cancer Therapy Pipeline 1 - Minichart
ALX Oncology names Jeff Knight as chief development officer - Investing.com
ALX Oncology Appoints Jeff Knight to Lead Development - TipRanks
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Bitget
Jeff Knight joins ALX Oncology (NASDAQ: ALXO) as development chief - Stock Titan
ALX brings in 30-year biotech veteran ahead of key cancer milestones - Stock Titan
Press Release: ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - Moomoo
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Profit Recap: What are the risks of holding ALX Oncology Holdings Inc2026 Final Week & Trade Opportunity Analysis - baoquankhu1.vn
Retail Trends: Can ALX Oncology Holdings Inc reach all time highs this year2026 Market WrapUp & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
LRMR stock on the move: What sparked the 55% jump in the past month? - MSN
Geopolitics Watch: Is ALX Oncology Holdings Inc attractive at current valuation2026 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Block Trades: Will ALX Oncology Holdings Inc benefit from government policyPortfolio Risk Report & High Accuracy Trade Signal Alerts - baoquankhu1.vn
What is driving long-term growth of ALX Oncology (ALXO) Stock | Price at $1.83, Down 6.63%Crowd Risk Alerts - Xã Thanh Hà
ALXO Technical Analysis & Stock Price Forecast - Intellectia AI
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Mar 19 '26 |
Sale |
2.17 |
903 |
1,960 |
86,805 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 18 '26 |
Sale |
2.27 |
565 |
1,283 |
87,708 |
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):